Liver King TRT: Public Transformation Timeline and What He Admitted to Taking

Who Is Liver King and Why Does His Case Matter Clinically?

Brian Johnson, better known as Liver King, built a social media following of over 10 million across platforms by promoting what he called the "nine ancestral tenets." Sleep, sunlight, cold exposure, and above all, eating raw organ meat were presented as the complete explanation for his physique. The claim had direct commercial consequences, driving supplement sales from his company Ancestral Supplements into the tens of millions of dollars annually.

The Clinical Stakes of the "Natural" Claim

Clinicians and researchers who study anabolic steroid use have long noted that celebrity "natural" claims shape patient behavior. A 2021 review in the British Journal of Sports Medicine found that media portrayals of attainable natural physiques contribute to body dysmorphia and non-prescribed anabolic steroid use in adolescent males, with prevalence of non-medical androgen use estimated at 1 to 6 percent among male high school students in the United States [1]. When a public figure with an extreme physique attributes it solely to lifestyle, the downstream effect on that population is not trivial.

Baseline Physique Before 2021

Johnson's earliest widely circulated photos, from the mid-2010s, show a muscular but not exceptional build consistent with serious recreational training. By 2021, his publicly visible body mass and vascularity had changed substantially. The rate and pattern of that change, specifically rapid increases in lean mass combined with very low body fat sustained year-round, are inconsistent with what exercise science literature describes as achievable through training and nutrition alone in a natural middle-aged male.

A meta-analysis of 49 randomized controlled trials found that unsupported resistance training in men produces mean lean mass gains of approximately 1.1 kg over 20 weeks [2]. Gaining and sustaining 20 or more kilograms of visible lean mass above natural ceiling is not a trajectory the peer-reviewed exercise physiology literature supports without pharmacological assistance.

The December 2022 Admission: What He Said and When

On December 2, 2022, Johnson posted a 45-minute YouTube video titled "Liver King Comes Clean." The video followed the leak of an email, attributed to Johnson, that had been sent to fitness influencer Derek of the channel More Plates More Dates. That email, later authenticated by Johnson, described a detailed PED protocol.

Contents of the Leaked Email

The email described a monthly pharmaceutical expenditure of approximately $11,000. Specific compounds mentioned included:

• Testosterone cypionate: cited at doses consistent with supratherapeutic use within a stacking context
• Recombinant human growth hormone (rHGH): 4 IU per day
• Insulin (Humalog): timed periworkout
• Winstrol (stanozolol): an oral 17-alpha alkylated anabolic steroid
• Deca-Durabolin (nandrolone decanoate): an injectable nandrolone ester
• Anavar (oxandrolone): a mild oral anabolic steroid often used during cutting phases
• IGF-1 (insulin-like growth factor 1): a peptide with anabolic downstream effects

In the YouTube video, Johnson confirmed the email's authenticity and stated: "I was wrong. I misled you. For that, I am sorry." He described ongoing therapy and expressed regret for promoting a false narrative to his audience.

Legal Context

Before the admission, a class-action lawsuit had been filed against Johnson and Ancestral Supplements on behalf of consumers who alleged they purchased products based on the implied promise that his physique was achievable through the ancestral lifestyle alone. The case proceeded through preliminary stages; settlement terms have not been publicly disclosed as of the date of this review.

Clinical Pharmacology of Each Admitted Compound

Understanding what Johnson described taking requires separating the clinical use of each compound from its misuse in a performance context. This section reviews each compound at the doses relevant to the disclosed protocol.

Testosterone and TRT: Therapeutic vs. Supratherapeutic Use

Testosterone replacement therapy (TRT) is an FDA-approved treatment for male hypogonadism, defined by the Endocrine Society as two morning serum testosterone measurements below 300 ng/dL combined with symptomatic hypogonadal features [3]. The typical therapeutic dose of testosterone cypionate in an FDA-approved protocol is 50 to 100 mg intramuscularly weekly, targeting mid-normal physiological range (400 to 700 ng/dL).

Supratherapeutic testosterone use, as described within a stacking context, pushes serum levels far above physiological range. A randomized dose-response trial published in the New England Journal of Medicine found that testosterone doses above 600 mg per week in healthy men produced significant increases in lean mass and strength, but also dose-dependent increases in adverse effects including erythrocytosis, dyslipidemia, and suppression of LH and FSH to near-zero [4]. Johnson's disclosed stack, combining testosterone with five additional anabolic agents, represents use well outside any therapeutic guideline.

Human Growth Hormone at 4 IU per Day

Recombinant HGH (somatropin) is FDA-approved for adult growth hormone deficiency at doses typically between 0.1 and 0.3 mg per day (approximately 0.3 to 1 IU per day), with diagnosis requiring stimulation testing [5]. The 4 IU per day dose disclosed in the leaked email is four to twelve times the upper range of approved replacement dosing.

A Cochrane review of HGH in healthy older adults found that supraphysiological HGH increased lean mass by approximately 2 kg but did not improve muscle strength, while substantially raising the risk of soft tissue edema, carpal tunnel syndrome, and arthralgias [6]. HGH also raises IGF-1 levels, and elevated IGF-1 is associated in epidemiological data with increased colorectal and prostate cancer risk, though causality in the context of exogenous administration has not been confirmed in long-term RCTs [7].

Insulin Use Outside Diabetes Management

Periworkout insulin use, as described in the leaked protocol, carries a direct and serious safety risk. Humalog (insulin lispro) is a rapid-acting insulin analog approved for diabetes management. In non-diabetic individuals, exogenous insulin suppresses hepatic glucose output and accelerates glucose uptake into muscle and adipose tissue. Without precise carbohydrate titration, severe hypoglycemia can result within 15 to 30 minutes of injection. The FDA labels insulin for diabetes management only; non-diabetic use is off-label and carries no established benefit-to-risk ratio that supports elective administration [8].

Nandrolone Decanoate (Deca-Durabolin)

Nandrolone decanoate is a synthetic anabolic-androgenic steroid with a higher anabolic-to-androgenic ratio than testosterone. It is approved in the United States for a narrow set of indications including anemia of renal disease. Its use in bodybuilding contexts is associated with suppression of the hypothalamic-pituitary-gonadal axis, cardiovascular remodeling, and, at sustained doses, left ventricular hypertrophy. A prospective study in Circulation examining long-term anabolic steroid users found significantly impaired left ventricular systolic function compared to age-matched controls, with nandrolone among the most frequently used agents in the cohort [9].

Stanozolol (Winstrol) and Oxandrolone (Anavar)

Both stanozolol and oxandrolone are oral 17-alpha alkylated steroids, a chemical modification that confers oral bioavailability but also imposes hepatotoxic potential. Stanozolol has a well-documented adverse lipid profile effect; a study in the Journal of Clinical Endocrinology and Metabolism demonstrated that stanozolol at 6 mg per day reduced HDL cholesterol by approximately 33 percent within three weeks [10]. Oxandrolone is less hepatotoxic than stanozolol and carries an FDA approval for weight regain after surgery or chronic infection, but supratherapeutic doses in athletes produce similar lipid and cardiovascular risks.

IGF-1 (Insulin-like Growth Factor 1)

IGF-1 mediates many of HGH's anabolic effects. Exogenous recombinant IGF-1 (mecasermin) carries an FDA approval only for severe primary IGF-1 deficiency in children with growth failure. In bodybuilding contexts, IGF-1 is used to amplify the anabolic signal already elevated by exogenous HGH. The combination raises theoretical concern for acromegalic features with prolonged use and for insulin-like hypoglycemia in the acute post-injection window [11].

What "TRT" Actually Means vs. What Johnson Described

The phrase "Liver King TRT" circulates widely in search queries, but the protocol described in the leaked email is not TRT in any clinical sense. TRT, when prescribed and monitored correctly, involves one androgen at physiological replacement doses, with regular monitoring of hematocrit, PSA, lipid panel, and serum testosterone.

The table below illustrates the clinical distinction clearly.

| Parameter | Supervised TRT | Disclosed Liver King Stack | |---|---|---| | Number of compounds | 1 (testosterone) | 7+ | | Testosterone dose | 50 to 200 mg/week | Supratherapeutic within stack | | HGH | Not included | 4 IU/day | | Insulin | Not included | Humalog periworkout | | Monitoring | Quarterly labs | Not disclosed | | FDA approval context | Hypogonadism | None for this combination | | Estimated monthly cost | $20 to $150 | ~$11,000 |

Supervised TRT at physiological doses does carry a well-characterized safety and efficacy profile. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and cardiovascular risk factors did not increase major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months, with a hazard ratio of 0.96 (95% CI 0.78 to 1.17) [12]. That finding applies to physiological-range TRT, not to the polypharmacy stack Johnson described.

Physical Transformation Timeline: What the Evidence Supports as Inference

Because Johnson did not disclose when he began using PEDs, the exact timeline remains unknown. What can be noted from publicly available photos and videos:

Phase 1 (Approximately 2015 to 2018)

Johnson was publicly active in ancestral health circles but not widely known. His physique in available images from this period is consistent with experienced natural resistance training. Lean mass is substantial but not outlying for a trained male in his late 30s.

Phase 2 (Approximately 2019 to 2021)

This period corresponds to the rapid growth of his social media presence. His physique became notably more extreme: increases in visible muscle mass across the upper body, sustained low body fat year-round, and a degree of vascularity that exercise physiologists have described as inconsistent with natural aging in a male approaching 45. This is the phase during which, based on the admitted PED protocol, pharmacological assistance was most likely ongoing. This remains an inference, not a confirmed start date.

Phase 3 (2022 to Present)

After the December 2022 admission, Johnson stated he was discontinuing PED use. Visible changes in his physique in the months following the admission were consistent with what endocrinologists describe as the natural regression that follows cessation of supraphysiological androgen and HGH administration: modest reduction in lean mass, some reduction in facial changes associated with HGH excess, and normalization of skin texture over several months.

The Endocrine Society notes that recovery of the hypothalamic-pituitary-gonadal axis after prolonged supratherapeutic androgen use may take 6 to 24 months, and in some men with prolonged heavy use, hypogonadism may persist indefinitely, requiring medically supervised TRT [13].

Health Risks of the Disclosed Stack: A Clinical Summary

The combination of compounds Johnson described carries risks across multiple organ systems.

Cardiovascular

Long-term anabolic steroid use is associated with left ventricular hypertrophy, reduced ejection fraction, and accelerated atherosclerosis. A case-control study published in Circulation found that former anabolic steroid users had a mean left ventricular ejection fraction of 52 percent compared to 63 percent in age-matched controls (P<0.001) [9]. Adding HGH to the stack amplifies cardiovascular remodeling risk through IGF-1-mediated cardiac hypertrophy pathways.

Hepatic

The oral 17-alpha alkylated agents (stanozolol and oxandrolone) impose hepatotoxic risk, including cholestatic jaundice and, with prolonged use, peliosis hepatis. Liver function testing is standard monitoring for any patient prescribed oral anabolic steroids [14].

Endocrine

Exogenous androgens suppress the hypothalamic-pituitary-gonadal axis completely at supratherapeutic doses, resulting in testicular atrophy and azoospermia. Fertility restoration after cessation is variable and may require clomiphene or HCG-based post-cycle therapy [15].

Metabolic

Insulin misuse in non-diabetic individuals creates acute hypoglycemia risk. IGF-1 excess is linked to insulin resistance over time. The combination of HGH, insulin, and IGF-1 creates a complex and difficult-to-predict metabolic environment outside any studied protocol.

What Patients Ask Clinicians After Cases Like This

Liver King's case generates real clinical conversations. Patients arrive at telehealth and in-person consultations asking whether TRT would give them a similar result, or whether the compounds Johnson named are available through legitimate channels.

The honest clinical answer: supervised TRT at physiological doses is a legitimate, evidence-supported treatment for hypogonadism with a favorable risk profile at therapeutic doses. The TRAVERSE trial and a 2018 meta-analysis in JAMA Internal Medicine (27 RCTs, N=2,399) both document modest but real improvements in body composition, sexual function, and bone density in hypogonadal men on supervised TRT [16]. Those outcomes are not the same as the extreme physique Johnson displayed.

The other compounds Johnson named, specifically supratherapeutic HGH, non-diabetic insulin use, and oral 17-alpha alkylated steroids for performance purposes, have no legitimate prescribing pathway for healthy individuals seeking physique enhancement. A board-certified endocrinologist or urologist can order serum testosterone, LH, FSH, and a complete metabolic panel to determine whether a patient is genuinely hypogonadal and whether TRT is medically indicated.